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Cytochrome P450 enzymes are often responsible for the toxic and carcinogenic effects
of toxicants, such as aflatoxin B1 (AFB1). The human hepatic CYP2A6 enzyme mediates
the oxidative metabolism of several procarcinogens. In this study, we characterized a
partial sequence of CYP2A6 gene from Arbor Acres (AA) broiler and studied its role
in AFB1 bioactivation. Moreover, the effect of curcumin on CYP2A6 is illustrated. Six
groups of AA broiler were treated for 28 days including the control group (fed only
basal diet), curcumin alone-treated group (450 mg/kg feed), the group fed AFB1-
contaminated feed (5 mg/kg feed) plus the low (150 mg), medium (300 mg) or high
(450 mg) of curcumin, and the group fed AFB1-contaminated diet alone (5 mg/kg feed).
After the end of treatment period, liver samples were collected for different analyses. The
results revealed that the histopathological examination showed clear signs of liver toxicity
in AA broliers in AFB1-fed group, but curcumin-supplementation in feed prevented
partially AFB1-induced liver toxicity. Liver and body weights were recorded to study the
AFB1 harmful effects. We noted an obvious increase in liver weight and decrease in body
weight in AFB1-fed group. But, the administration of curcumin partially ameliorated the
increase in liver weight and decrease in body weight in a dose-dependent manner. The
results (RT-PCR and Elisa) revealed that mRNA and protein expression level enhanced
in AFB1-fed group. Consistently, CYP2A6 enzyme activity also increased in AFB1-fed
group, suggesting that AA broiler CYP2A6 actively involved in bioactivation of AFB1.
However, curcumin treatment inhibited CYP2A6 at mRNA and protein levels in AFB1
treated AA broiler in a dose-dependent manner. Maximum inhibition of liver CYP2A6
enzyme activity in AA broiler has been achieved at a dose of 450 mg/kg curcumin.
This is the first study identifying and confirming the role of CYP2A6 enzyme in AFB1
bioactivation in AA broiler liver (in vivo), and the hepatoprotective role of curcumin via
inhibiting CYP2A6 expression and enzyme activity. The study contributed to identify an
important CYP enzyme involved in AFB1 bioactivation in broilers and thus could pave
the way for the prevention of the harmful effects of AFB1 in broilers.
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INTRODUCTION
Cytochrome P450 (CYP) enzymes metabolize various exogenous
and endogenous compounds (Nelson et al., 1996). It is well
understood that several CYP isoforms involved in carcinogenesis
process by metabolically activating procarcinogens to its
highly active, DNA-binding metabolites (Gonzalez and
Gelboin, 1994). Aflatoxins are well known hepatotoxic,
hepatocarcinogenic and mutagenic agents for both animals
and humans. These are the food-borne secondary toxic fungal
metabolites produced during the growth of Aspergillus flavus
and A. parasiticus (Verma, 2004). Aflatoxin B1 (AFB1) is
considered the most biologically active form. It is being
increasingly identified that long-term consumption of low
levels of this mycotoxin can be harmful to human and animal
health. AFB1 is concerned with hepatotoxicity, genotoxicity,
carcinogenicity, immunosuppression and other undesirable
effects in many animal species including poultry (Richard,
2007; Rawal et al., 2010a). It could be bioactivated in liver
by cytochrome P450 enzymes (CYP450) to a highly reactive
electrophilic and unstable metabolite that is able to react with
cellular macromolecules causing genotoxicity (reacts with
DNA) and cytotoxicity (react with proteins) (Doi et al., 2002;
Cervino et al., 2007). Some earlier studies reported that the
main CYP enzymes responsible for the biotransformation
of AFB1 into aflatoxin-8,9-epoxide (AFBO) in mammals
were CYP2A6, CYP1A2 and CYP3A4. (Gallagher et al., 1996;
Guengerich et al., 1996, 1998). Kamdem et al. (2006) identified
in human that CYP3A4 is the main enzyme responsible for
AFB1 bioactivation into AFQ1 and aflatoxin-8,9-epoxide, and
the main metabolite of AFB1 was AFQ1 (63–95%) (Kamdem
et al., 2006). The enzymatic activities of CYP1A1, CYP1A2,
CYP2A6 and CYP3A4 have been detected earlier in chickens
and quails liver microsomes. A strong correlation has been
demonstrated between the activities of CYP2A6 and CYP1A1 (to
a lesser extent) with the biotransformation of AFB1 into AFBO.
The AFBO production rate is higher in liver microsomes of
quail compared with chickens which could partially explain the
higher sensitivity of quail to aflatoxins (Diaz et al., 2010). Rawal
et al. (2010b) reported that chicken CYP3A37 bioactivate AFB1
to aflatoxin-8,9-epoxide and AFQ1 and was suggested to play
a crucial role in avian xenobiotic metabolism relative to other
CYP3A, and chicken CYP3A37 isoform shows 60% similarity
with human CYP1A4 (Ourlin et al., 2000). Sensitivity to AFB1
by poultry species not only related to biotransformation of
AFB1 by Phase I enzymes but also to conjugation of AFBO with
glutathione (Phase II enzymes) (Diaz et al., 2010). The highly
electrophilic metabolite (aflatoxin-8,9-exo-epoxide) of AFB1
binds to guanine residues in nucleic acids causing mutations in
DNA and leading to liver cancer in ducks, humans, and primates
(Eaton and Gallagher, 1994; Verma, 2004; Do and Choi, 2007).
CYP2A6 is the primary P450 involved in catalyzing nicotine to
cotinine in human (Messina et al., 1997). The increased
expression of CYP2A6 enzyme has been involved in greater
risk of liver cancer in human populations where aflatoxin
exposure is common and over expression of CYP2A6 protein
was associated with cirrhosis and chronic inflammation
(Kirby et al., 1993). CYP2A6 enzyme also catalyzes several
human procarcinogens and promutagens, including the
carcinogen AFB1 (Yun et al., 1991; Salonpaa et al., 1993). Thus,
it is suggested that CYP2A6 may also serve as indicator for
hepatic toxicity. Moreover, it has been previously reported that
CYP2A6 was responsible for the bioactivation of AFB1 into
AFBO in both quail and chicken hepatic microsomes (in vitro
study) (Diaz et al., 2010). However, only limited information
is available regarding chicken CYP2A6 and whether broiler has
CYP2A6 and its role in bioactivation of AFB1 has been seldom
reported.
Only very few medicinal plants bewitch the interest of
scientists, and one such plant is Curcuma longa Linn. Turmeric,
a yellow product in the rhizomes of Curcuma longa Linn
possess anti-inflammatory activity (Srimal and Dhawan, 1973;
Mukhopadhyay et al., 1982), and antioxidant properties (Sharma,
1976; Araujo and Leon, 2001). It has been considered as
a potential third generation cancer chemopreventive agent
by oncologists (Lin and Lin-Shia, 2001) and showed highly
protective effects against AFB1 (Soni et al., 1997). It is reported
earlier that curcumin modulates the activity of microsomal
enzymes (phase-I enzymes) and has the potential to control
chemical carcinogenesis (Firozi et al., 1996). It has been
shown previously that turmeric pretreatment decreased the
Benzo[a]Pyrene-induce phase-I enzymes such as CYP1A1/1A2
activity in tissues of rat (Thapliyal and Maru, 2001) and
down-regulation of CYP1A1 and CYP2H1 gene in chickens
(Yarru et al., 2009a). So far, whether could curcumin, an
antioxidant found in turmeric (Curcuma longa) powder,
modulate the activity of CYP2A6 of broiler fed AFB1 is
unknown.
Based on the postulated role of the chicken CYP2A homolog
in the sensitivity toward AFB1, the importance of CYP2A6
in the toxicology of AFB1 in humans and animals, and its
genetic implication in hepatic cellular cancer (HCC), lung cancer,
colorectal cancer etc., we hypothesize that the broilers has the
homologue of human CYP2A6 that may bioactivate AFB1. The
objectives of our study are: (1) to identify liver CYP2A6 ortholog
in chicken liver that has AFB1 oxidizing activity and partially
characterize this gene from AA broiler liver; (2) to investigate
whether curcumin supplementation of AA broiler diets could
affect the transactivation of CYP2A6 enzyme.
MATERIALS AND METHODS
Chemicals and Reagents
Pure AFB1 (purity ≥ 99.0%) was purchased from Sigma–
Aldrich (St. Louis, MO, USA). Absolute ethanol (99.0%),
methanol, isopropanol, chloroform, agarose G-10, sodium
chloride (NaCl) and glycine were bought from Tian
Li Company Ltd. (Tianjin, China). Curcumin (2.5%)
was bought from Shengxing chemical product company
Ltd. (Henan, China). Hematoxylin was purchased from
Guangzhou Chemical Reagent Company (China) and eosin
was purchased from Nanjing Chemical Reagent Factory
(China).
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Arbor Acres (AA) Broiler and
Experimental Protocol
Healthy AA broiler chickens were purchased from an authorized
(Registration number; 230108799294096) commercial hatchery
(Yi Nong, Harbin, Heilongjiang, China). The broilers were
weighed and assigned to different cages. Proper bedding material
provided and divided into six groups. Each group provided
randomly with 20 chicks. The AA broilers were kept on 12 h
light and 12 h dark, fed under standard managemental conditions
and AA broiler mortality was recorded during the trial period.
All of the experiments were conducted under the supervision
of the Harbin Veterinary Research Institute of the Chinese
Academy of Agricultural Sciences in accordance with animal
ethics guidelines and approved protocols. The Harbin Veterinary
Research Institute Animal Ethics Committee approval number
was SYXK (Hei) 2012-2067. Aflatoxin binder free diet was
purchased from Shen Nong Feed Company (Harbin, PR China).
Six dietary treatments included (1) CG; basal diet supplemented
with 0 mg AFB1/kg feed and 0 mg curcumin/kg feed (control
group, CG) (2) CCG; basal diet supplemented with 450 mg
curcumin/kg feed (curcumin control group, CCG) (3) R1G;
basal diet supplemented with 5.0 mg AFB1/kg feed and 150 mg
curcumin/kg feed (4) R2G; basal diet supplemented with 5.0 mg
AFB1/kg feed and 300 mg curcumin/kg feed (5) R3G; basal
diet supplemented with 5.0 mg AFB1/kg feed and 450 mg
curcumin /kg feed (6) AFB1 G; basal diet contaminated with
5.0 mg AFB1/kg feed (AFB1 group). 10 mg of AFB1 was first
dissolved in a known volume of methanol (30 ml). Then, the
AFB1-methanol solution was evenly sprayed over the feed and
thoroughly mixed to obtain the required concentration of AFB1
(5 mg AFB1/kg feed), and finally the feed air-dried at 37◦C.
AFB1 is toxic and should be handled with great care to avoid
contact/inhalation. It should only be handled in a fume hood
while wearing gloves, lab coat, and goggles (to protect eyes) and
all contacted materials should be properly disposed of in an
environmentally safe manner.
Sample Collection, Body Weight, Liver
Weight and Liver Index
After receiving the diets for 28 days, AA broiler chickens
were sacrificed by cardiac puncture following euthanasia with
sodium pentobarbital in an antiseptic environment. Body weights
were recorded before euthanasia. The entire liver was collected
and weight was recorded. The liver index reflected the liver
weight/body weight ratio. A piece of liver tissue (10–14 g) was
stored at−80◦C for further analysis.
Histopathological Examination
Liver histopathology was evaluated via hematoxylin and eosin
(HE) staining (Wang X.H et al., 2016). In brief, fresh liver tissue
pieces (1 cm × 1 cm) were fixed in 10% formalin for more than
24 h, after processed in a series of graded ethanol and dimethyl
benzene, then embedded in paraffin. Tissue sections (4 µm) were
sliced and mounted on glass slides. The slides were then stained
with HE for histopathological examination and were examined
under a light microscope (Nikon E100, 40X magnification).
Primer Designing for CYP2A6 and
Sequencing of the PCR Product
As CYP2A6 gene sequence is unknown in AA broiler but it was
predicted previously (Gonzalo and Hansen, 2011). Degenerate
primers were designed for CYP2A6 gene on the bases of the
sequence alignments (ClustalW) of homologous genes of
Human (CYP2A6; NP_000753.3, CYP2A7; NP_000755.2),
Rhesus monkey (CYP2A24; NP_001035305.1), Mouse (CYP2A5;
NP_031838.2), Rat (CYP2A3; NP_036674.1), Frog (CYP2A6;
NP_001010998.1) and Caenorhabditis elegans (CYP36A1;
NP_492267.1) by Codehop program1. The best score primers
were selected for PCR. The forward and reverse sequence
of the primer are TGTGCGCCGTCATC cangarrtnya-3′ and
acrranccnct CCCGGACCGGGC-5′ respectively. The optimum
PCR conditions were as follows: initial denaturation step at 95◦C
for 4 min; 95◦C for 10 s (denaturation); 58◦C for 10 s (annealing);
35 cycles at 72◦C for 25 s (elongation); and 72◦C for 5 min (final
extension step)2. The PCR product was then cloned under UV
light and sent for sequencing to the Sangon Biotech (Shanghai,
China). The sequencing result was blast in National Centre for
Biotechnology Information (NCBI) and a phylogenetic tree was
constructed.
1http://blocks.fhcrc.org/codehop.html
2http://www.eeescience.utoledo.edu/Faculty/Sigler/Von_Sigler/LEPR_Protocols_
files/PCR.pdf
TABLE 1 | Liver weight, body weight and liver index.
Treatments Liver weight (g/bird) Body weight (g/bird) Liver index (liver weight/body weight)
CG 22.673 ± 1.543 996.667 ± 20.276a,b,c,d,e,f 0.022803 ± 0.002a,c,f
CCG 18.144 ± 0.859a 876.4 ± 13.71a,b,c,d,f 0.0207 ± 0.001b,c,d,f
R1G 26.238 ± 1.523a 677.6 ± 16.467a,b,c,e 0.0389 ± 0.003a,b,c,e
R2G 23.93 ± 2.65 754.8 ± 26.442a,b,d,f 0.0322 ± 0.004b,d,f
R3G 22.028 ± 0.597b 830 ± 15.093a,c,e,f 0.0266 ± 0.0007c,e,f
AFB1G 29.538 ± 1.914a,b 612 ± 20.271a,b,d,f 0.048 ± 0.0025a,b,d,e,f
Treatment indicated as CG = Control group (basal diet), CCG = Curcumin control group (450 mg curcumin /kg feed), R1G = 150 mg curcumin + 5.0 mg AFB1/kg
feed, R2G = 300 mg curcumin + 5.0 mg AFB1/kg feed, R3G = 450 mg curcumin + 5.0 mg AFB1/kg feed, AFB1 G = 5.0 mg AFB1/kg feed. Values represented as
mean ± standard error (SE). The value (mean ± SE) of control group shows three observations (n = 3), while the remaining values shows five observations per group
(n = 5). Means with different letters statistically significant according to Tukey’s HSD test (p ≤ 0.05).
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FIGURE 1 | Chicken hepatic pathology. Liver sections were stained by hematoxylin and eosin and examined by light microscopy (40X magnification). (A) Control
group (CG; fed only basal diet), (B) Curcumin control group (CCG; 450 mg curcumin/kg feed), (C) Low dose curcumin group (R1G; 150 mg curcumin + 5.0 mg
AFB1/kg feed), (D) Medium dose curcumin group (R2G; 300 mg curcumin + 5.0 mg AFB1/kg feed), (E) High dose curcumin group (R3G; 450 mg
curcumin + 5.0 mg AFB1/kg feed), (F) AFB1 group (AFB1 G; 5.0 mg AFB1/kg feed). (H&E, scale bar = 10 µm).
Extraction of RNA and Real-Time PCR
Examination
Hepatic total RNA was isolated using the TRIzol extraction
method according to the manufacturer’s instructions (Invitrogen
Inc., Carlsbad, CA, USA). The RNA quality was verified by
evaluating the optical density at 260 and 280 nm (Wang
J et al., 2016). A high quality RNA was prepared, reverse
transcribed to cDNA using a first strand cDNA synthesis
kit (Toyobo, Co., Ltd. Osaka, Japan) and was subjected to
RT-PCR containing specific primers for the gene CYP2A6
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as the loading control gene in the LightCycle instrument
(Roche). The CYP2A6 forward and reverse primer used
for RT-PCR are CTGCAGAGAATGGCATGAAG and
CCTGCAAGACTGCAAGGAA respectively. The kit used
for RT-PCR were purchased from Toyobo Company Ltd.
(Japan). Data were analyzed and quantified using the 2−11Ct
method (Livak and Schmittgen, 2001).
Measurement of CYP2A6 Enzyme
Activity
Microsomal CYP2A6 activity was determined by measuring
the coumarin 7-hydroxylase (COH) level using the method as
described by Li et al. (2013). Briefly, a piece of liver tissue
was weighed (150–200 mg), cut with scissor and lysed in
homogenization buffer (pH 7.4), and microsomal extracts were
extracted by a series of differential centrifugations at 4◦C using
Beckman ultra-high speed centrifuge. Then 0.1 mg of microsomal
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protein was incubated with 100 mM coumarin and NADPH
for 15 min at 37◦C in a shaking incubator. The excitation and
emission wavelength for Fluorescence was set at 355 and 460 nm
respectively using a Fluoroskan Ascent (Thermo Fisher Scientific,
Shanghai, China).
CYP2A6 Specific Protein Linked
Immunosorbant Assay (ELISA)
The monoclonal CYP2A6 ELISA kit (competitive enzyme
immunoassay) bought from Bio-Source Company Ltd (Southern
California, San Diego, CA, USA). The assay was done according
to the manufacturer instructions. Liver tissue samples were
weighed (300–350 mg), rinsed in ice-cold PBS (pH 7.0 – 7.2)
to remove excess blood before homogenization. The tissue
were minced and then homogenized in a tissue homogenizer
(Shanghai, China) in 500 µl of PBS. The resulting suspension
was subjected to ultrasonication and centrifuged for 15 min
at 5000 rpm. The supernatant was taken, diluted and assayed
immediately. All the samples and standards along with a blank
control were run in duplicate and the readings were taken
at 450 nm using an iMARKTM microplate reader (Bio-Rad
Co., Ltd. Shanghai, China) and the protein concentration was
quantified.
Statistical Analysis
All the assays were performed in triplicates unless otherwise
mentioned. Significance of the data were measured by statistical
package for social science (SPSS, version 21.0). Differences
between groups were analyzed by one way ANOVA followed
by Tukey’s test and p < 0.05 were considered statistically
significant. The results expressed as mean ± standard error. All
the graphs with standard error bar were made on SigmaPlot
(Version 10.0).
RESULTS
AA Broiler Mortality, Health and
Phenotypic Effects of AFB1
We have observed no (zero) mortality in all experimental groups
during the 28 days trial period. The broiler fed curcumin alone
(CCG) showed no significant abnormal signs. Compared to CG
and CCG, impaired feathering, lethargy and yellow skin were
observed in broiler chickens fed AFB1. These signs disappear
with curcumin treatment in all the three groups (R1G, R2G,
and R3G). Ruﬄed feathers were noted in AA broiler chickens
in low dose curcumin group (R1G). In order to study the
phenotypic effects of AFB1, liver weight and body weight of AA
broiler chickens were recorded. The increase in liver weight was
statistically significant (p < 0.05) in AFB1-fed group compared
to CCG, but was not statistically significant relative to CG as
shown in Table 1. Body weights were also decreased significantly
(p < 0.05) in AFB1 fed group as compared to control group
and curcumin control group, which provide an insight into
the mechanism of toxicity. However, the addition of curcumin
partially ameliorated the increase in liver weight and decrease in
FIGURE 2 | The PCR product was run and visualized on 1.0% agarose
gel and a clear band (294 bp) was obtained for primer 3 (P3). The
Marker (M) 2 Kbp was loaded in Lane1, while the three different PCR products
were loaded in the consecutive lanes (P1; Lane 2, 3 P2; Lane 4, 5 and P3;
Lane 6, 7). The molecular weight (bp) corresponding to the DNA ladder is
indicated on the left side.
body weight in a dose dependent manner (R1G, R2G, and R3G).
It is noted that 450 mg/kg curcumin (R3G) treatment achieved
maximum amelioration against AFB1-induced increase in liver
weight and decrease in body weight (Table 1).
Histopathological Examination
Figure 1 shows the photomicrographs of HE-stained liver
sections of AA broilers. There were no microscopic lesions in
the livers of broilers received control diet (Figure 1A) and
broilers fed control diet plus curcumin (Figure 1B). AFB1 group
(Figure 1F), and the AFB1 plus low dose of curcumin group
(Figure 1C) showed a severe liver damage, vacuolar degeneration,
fatty degeneration and ballooning of the hepatocytes relative
to control group (Figure 1A). As compared to control group
(Figure 1A), medium dose group (Figure 1D) showed moderate
congestion and vacuolar degeneration. While the high dose
curcumin group (Figure 1E) showed granular degeneration in
hepatocytes relative to control group (Figure 1A). Thus, these
results showed that low dose curcumin had no effect in the
prevention of liver damage induced by AFB1, while the medium
and high dose curcumin can prevent liver injury partially. As the
amount of curcumin increased in the diet, the amelioration effect
of curcumin becomes more apparent, especially with the high
dose (450 mg/kg) curcumin-treated group (Figure 1E).
Sequencing of PCR Product and
Construction of Phylogenetic Tree
As chicken CYP2A6 gene nucleotide sequence was unknown but
this gene was predicted in earlier studies that the putative avian
CYP2A6 ortholog may be the main CYP450 enzyme responsible
for the bioactivation of AFB1 into its epoxide form in poultry
species (Gonzalo and Hansen, 2011). In this study, we identified
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FIGURE 3 | The nucleotide sequence for the chicken CYP2A6 gene has been deposited in the GenBank database under GenBank accession number
KX687985. A phylogenetic tree was generated by the neighbor-joining method using distance relationships by using MEGA4 software. The genes accession
numbers selected for the phylogenetic tree are as follows: Gallus gallus CYP2H1 like (NM_001001616.1), Gallus gallus CYP2C8 (NM_001001757.1), Coturnix
japonica cytochrome P450 2H1-like (XR_001556094.1), Meleagris gallopavo cytochrome P450 2H1-like (XM_010714529.1), Crossoptilon auritum CYP2C23a (dbj|
AB795991.1), Anser cygnoides domesticus CYP2H1-like (XM_013178097.1), Meleagris gallopavo CYP2H2 (XM_010714446.1), Anas platyrhynchos CYP2H1
(XM_013104761.1), Charadrius vociferus CYP2H1-like (XM_009888733.1), Gavia stellata CYP2H1-like (XM_009819531.1), Bubo scandiacus CYP2C23a (dbj|
AB795985.1), Colius striatus cytochrome P450 2H1-like (XM_010203599.1), Haliaeetus leucocephalus CYP2H1-like (XM_010563515.1), Acanthisitta chloris
CYP450 2H1-like (XM_009081538.1), Gallus gallus putative CYP2A6 (KX687985).
and characterized a partial sequence of AA broiler CYP2A6
gene by designing degenerate primers as stated in materials
and methods. The PCR product (Figure 2) was sequenced and
blast in NCBI. The nucleotide sequence for the putative broiler
CYP2A6 gene has been deposited in the GenBank database under
GenBank accession number KX687985. Sequence alignment of
this sequence shows similarity to mouse CYP2A5 isoform (50%)
and human CYP2A6 (49%). The phylogenetic tree was made
based on the nucleotide sequence of putative broiler CYP2A6
and the CYP2 family enzymes, selected for the phylogenetic
tree which shows a similarity more than 85% according to blast
results. The nucleotide sequences were aligned using ClustalW
and employed for model selection and construction of maximum
likelihood tree using MEGA4 (Figure 3). The tree indicates that
the characterized sequence is a gene of CYP2 family.
Effect of AFB1, Curcumin and
AFB1-Curcumin Diets on CYP2A6 mRNA
Expression
A slight reduction of mRNA expression level has been noted in
curcumin alone group (CCG) as compared to CG (Figure 4).
The group fed AFB1 (AFB1 G) showed significant (p< 0.05) up-
regulation of CYP2A6 mRNA expression level relative to CG. On
the other hand, a dose-dependent reduction of CYP2A6 mRNA
expression level has been noted in AFB1-curcumin treated groups
(R1G, R2G, and R3G). Thus, the increased expression of CYP2A6
mRNA expression due to AFB1 has been reduced by curcumin
and maximum reduction observed at a dose of 450 mg/kg
curcumin treatment (R3G).
Inhibition of CYP2A6 Enzyme Activity by
Curcumin
Figure 5 shows the effect of different diets on CYP2A6
enzyme activity. It is observed that CYP2A6 activity is
slightly reduced in curcumin alone group (CCG) relative
to CG. Compared to CG and CCG, CYP2A6 activity has
been significantly (p < 0.05) increased in AFB1 fed group
(AFB1G), shows its involvement in AFB1 bioactivation.
However, the three different doses of curcumin reduced the
enzyme activity in a dose-dependent manner (R1G, R2G,
and R3G). It is clear that 450 mg/kg curcumin treatment
(R3G) effectively (p < 0.05) inhibited the enzyme activity of
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FIGURE 4 | The values represented as mean ± SE (n = 3). CG, control group (fed only basal diet); CCG, curcumin control group (450 mg curcumin/kg feed);
R1G = 150 mg curcumin + 5.0 mg AFB1/kg feed, R2G = 300 mg curcumin + 5.0 mg AFB1/kg feed, R3G = 450 mg curcumin + 5.0 mg AFB1/kg feed, AFB1
G = 5.0 mg AFB1/kg feed. The value of P < 0.05 was considered statistically significant. Means with different letters significantly different according to Tukey’s HSD
test (p ≤ 0.05).
CYP2A6 relative to AFB1 group (AFB1G). Hence, we explored
that curcumin has an inhibitory effect on CYP2A6 enzyme
activity.
Effect of AFB1, Curcumin and
AFB1-Curcumin Diets on CYP2A6
Protein Expression
Compared to CG, CYP2A6 protein expression reduced in
curcumin alone group (CCG), but significantly (p < 0.05)
increased in AFB1 fed group (AFB1 G) (Figure 6). Figure 6
also shows that the protein expression reduced in a dose-
dependent manner with different treatments of curcumin
along with AFB1 exposure (R1G, R2G, and R3G). Thus,
curcumin effectively decreased the enhanced protein
expression of CYP2A6 due to AFB1, and significant reduction
(p < 0.05) in protein expression is achieved with 450 mg/kg
curcumin treatment (R3G) compared with AFB1 fed group
(AFB1 G).
DISCUSSION
This study utilized in vivo exposure model to study the harmful
effects of AFB1 in AA broiler chickens. The supplementation of
curcumin alone in the diet did not have a significant effect on
liver weight but significantly (p < 0.05) effect the body weight
of AA broiler chickens compared to control group. However,
as stated in results section, curcumin partially ameliorated the
AFB1-induced increase in liver weight and decrease in body
weight with the increasing doses of curcumin. The failure of
curcumin to further ameliorate the AFB1-induced increase in
liver weight and decrease in body weight, it is still unknown.
Since, the abnormal changes in liver weight and body weight
(compared to control group) is not the only mode of action of
AFB1, but there are also some other toxic effects of AFB1 and
it has been shown earlier that AFB1 decreased the expression
of hepatic genes involved in fatty acid metabolism, energy
production, coagulation, detoxification and immunity of male
broiler chicks (Yarru et al., 2009b). Our findings of AFB1
harmful phenotypic effects (Table 1), are in consistent with
earlier studies, that dietary AFB1 in poultry causes increase in
liver weight due to lipid accumulation in liver, which results
in hepatomegaly and increased liver weight in both chickens
and domesticated turkeys (Giambrone et al., 1985; Yarru et al.,
2009a; Chen et al., 2014). In addition to these phenotypic
changes, hepatic transcriptome analysis showed significant effects
on genes involved in cell cycle regulation and NRF2-pathway
(Monson et al., 2016). Our histological findings showed severe
liver injury in AFB1 fed group. However, the supplementation
of curcumin in increasing doses did not completely ameliorate
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FIGURE 5 | Enzyme activity of CYP2A6 enzyme (coumarin biotransformation). The data represented as mean ± SE (n = 3). CG, Control group (fed only basal
diet); CCG, Curcumin control group (450 mg curcumin/kg feed); R1G = 150 mg curcumin + 5.0 mg AFB1/kg feed, R2G = 300 mg curcumin + 5.0 mg AFB1/kg feed,
R3G = 450 mg curcumin + 5.0 mg AFB1/kg feed, AFB1 G = 5.0 mg AFB1/kg feed. The value of P < 0.05 was considered statistically significant. Means with
different letters significantly different according to Tukey’s HSD test (p ≤ 0.05).
liver injury in this study. These findings are in line with
some earlier studies reported about liver injury, toxicity of
aflatoxin and the chemopreventive effects of curcumin. (Gowda
et al., 2009; Yildirim et al., 2011; Colakoglu and Donmez,
2012).
Diaz et al. (2010) speculated earlier that the putative
avian CYP2A6 ortholog may be the main CYP450 enzyme
responsible for the bioactivation of AFB1. They found the
inhibition of aflatoxin-8,9-epoxide (AFBO) by specific CYP2A6
inhibitor and determined the relationship between CYP2A6
enzyme activity and AFBO formation. In this study, we
identified AA broiler CYP2A6 gene and characterized its
partial sequence. The phylogenetic tree (Figure 3), indicates
that the characterized sequence belongs to CYP2 family. It
is clear from our results that CYP2A6 is actively involved
in AFB1 bioactivation in broiler. Thus it is concluded that
CYP2A6 is one of major CYP enzyme that is responsible for
the biotransformation of AFB1 in broiler, and these results
are in agreement with the study conducted by Diaz et al.
(2010) who reported that over expression of chicken CYP2A6
related to aflatoxin-8,9-epoxide (AFBO) production and cause
AFB1-DNA adducts. The author also evaluated that CYP2A6
enzyme involved in AFB1 bioactivation in poultry species (duck,
quail, turkey, and chicken), and that AFBO production was
inhibited by the CYP2A6 inhibitor 8-methoxypsoralen and a
significant correlation between coumarin 7-hydroxylation and
AFB1 epoxidation had been demonstrated. In addition, CYP1A1,
CYP1A2 and CYP3A4 also bio-activate AFB1 into its toxic
metabolites in chicken, quail, turkey, and duck liver microsomes
(Hansen et al., 2011).
It has been showed previously that curcuminoids yellowish
pigments present in rhizomes of turmeric (Curcuma longa)
alleviate the harmful effects of AFB1 (Lee et al., 2001),
inhibit the biotransformation of aflatoxins to their epoxide
metabolites (Soni et al., 1997), and reverse the aflatoxin
induced liver damage (Soni et al., 1992). Curcumin potently
inhibited CYP3A activity in rats (Kim et al., 2015), CYP2D6,
CYP2B6, CYP1A2, CYP3A4 and CYP2C9 in human (Appiah-
Opong et al., 2007). Our data showed that curcumin has
alleviated the enhanced protein and mRNA expression of broiler
CYP2A6 enzyme. In addition, we found that the elevated
mRNA expression and protein expression of broiler CYP2A6
enzyme due to AFB1, decline with dietary curcumin in a
dose-dependent manner. Moreover, curcumin decreased the
broiler CYP2A6 enzyme activity in dose-dependent manner,
thus reducing the AFB1-DNA adduct formation and inhibited
the enzymatic formation of AFB1 metabolites in AA broiler
chickens. Hence, we explored that curcumin has an inhibitory
effect on the activity of CYP2A6 and thus curcumin would
be a valuable drug in preventing the AFB1 toxicity. Maximum
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FIGURE 6 | The effect of AFB1, curcumin and AFB1-curcumin treatment on protein expression of CYP2A6 relative to control group. The value of
P < 0.05 was considered statistically significant. The data represented as mean ± SE (n = 3). The groups represented as CG = Control group (fed only basal diet),
CCG = Curcumin control group (450 mg curcumin/kg feed), R1G = 150 mg curcumin + 5.0 mg AFB1/kg feed, R2G = 300 mg curcumin + 5.0 mg AFB1/kg feed,
R3G = 450 mg curcumin + 5.0 mg AFB1/kg feed, AFB1 G = 5.0 mg AFB1/kg feed. Different superscript letters indicate that means significantly different according
to Tukey’s HSD test (p ≤ 0.05).
inhibition of broiler CYP2A6 mRNA elevated expression had
been achieved at high dose (450 mg/kg) curcumin treatment
along with AFB1 (5.0 mg/kg) dietary exposure. The protein
expression of CYP2A6 showed the same trend as the mRNA
expression. This finding is further evaluated by enzyme activity
measurement which also showed that high dose curcumin
inhibited liver increased CYP2A6 enzyme activity in broiler
fed with AFB1 contaminated diet. Similarly, it has been stated
earlier that curcumin alleviated the increased expression of
CYP2H1 and CYP1A1 in chickens fed AFB1 while increased
the expression of certain phase-II enzymes such as GST
(Yarru et al., 2009a). Moreover, curcumin further resulted in
decreased carcinogen-induced stress and DNA adducts and
the inhibitory effects of dietary curcumin on Benzo[a]Pyrene-
induced AhR activation and decline in protein expression
and enzyme activity of CYP1A1/1A2 (in vivo) in mice has
also been reported (Garg et al., 2008). In addition, curcumin
reduces the levels of superoxide anion formation (Lee et al.,
2001), and biotransformation of aflatoxicol in liver (Iqbal
et al., 2003). Compared to controls, our data showed that
150 mg/kg and 300 mg/kg curcumin supplementation in
diet not fully reduced the increased enzyme activity of
broiler liver CYP2A6 along with AFB1 feeding. The mRNA
and protein expression results are also in consistent with
this finding. Gowda et al. (2009) who demonstrated that
dietary supplementation of 74 mg/kg curcumin not completely
ameliorated the adverse effects of AFB1 but 222 mg/kg
curcumin provided the greatest amelioration in broiler chickens
against 1.0 mg/kg dietary AFB1. Our current in vivo findings
showed that 450 mg/kg dietary curcumin fully alleviated the
increased expression of broiler liver CYP2A6 enzyme against
5.0 mg/kg dietary AFB1. Although the molecular mechanism
of inhibition is still unknown and needs further studies to be
verified. AFB1 is hazardous due to their potential hepatotoxicity
and carcinogenicity, and AFB1-epoxides are potent mutagenic
agents. Thus, inhibition of phase-I and enhancement of phase-
II enzymes in liver appear to play highly significant role
in preventing AFB1-induced hepatocellular carcinogenesis and
mutagenesis.
CONCLUSION
This is the first study to characterize the partial sequence of
liver CYP2A6 gene in AA broiler, which may help in cloning
and complete molecular characterization of CYP2A6 gene, in
future, to further define its role in various drug and toxin
induced toxicities. Our findings suggest that curcumin protects
liver from AFB1 toxicity, and that higher doses of curcumin
negatively modulates the bioactivation of AFB1. Additionally, the
effect of curcumin on CYP2A6 enzyme has been demonstrated
along with AFB1 exposure. Taken together, our findings may
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provide an insight into the mechanism of AFB1-induced
hepatotoxicity in broiler liver and the preventive effects of
curcumin against AFB1.
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